NEW YORK (GenomeWeb) – Trovagene announced today that it will collaborate with the University of Southern California Norris Comprehensive Cancer Center on the best way to use its Trovera urine liquid biopsy test in the clinic.
Under the terms of the agreement, the partners will establish a framework for the use of Trovera and general best practices for liquid biopsy testing from urine. They will also develop algorithms to determine how and when to use liquid biopsy technology.
Trovera analyzes circulating tumor DNA (ctDNA) in urine to find EGFR, KRAS, and BRAF mutations in patients and to assess potential response to therapy.
"The clinical data Trovagene has presented and published thus far illustrate the tremendous promise of using urinary ctDNA as a noninvasive sample type to detect and monitor clinically actionable oncogene mutations, and provide essential molecular information about a patient's disease," USC Norris Comprehensive Cancer Center Director Stephen Gruber said in a statement.
The agreement marks the latest in a string of collaborations for Trovagene. Earlier this month, the firm announced a collaboration on pancreatic cancer with the University of Michigan. In 2015, Trovagene began a collaboration with the University of California, San Diego to monitor EGFR mutations in lung cancer.